Jonathan served as CEO of Olfax from 2021 to 2026, guiding the company through early product development, non-dilutive funding, and its transition toward clinical-stage development. He now supports Olfax in an advisory capacity, focused on non-dilutive funding strategy — drawing on his track record securing  over $6M in SBIR, DoD, and state economic development awards that have supported the company’s growth.